Logo image
Back
The pharmacologic management of depression in Parkinson's disease
Journal article   Open access   Peer reviewed

The pharmacologic management of depression in Parkinson's disease

Matthew A. Schreiber and Alexander W. Thompson
Degenerative neurological and neuromuscular disease, Vol.3, pp.1-9
01/01/2013
DOI: 10.2147/DNND.S36917
PMCID: PMC6065611
PMID: 30890888
url
https://doi.org/10.2147/DNND.S36917View
Published (Version of record) Open Access

Abstract

Depression in Parkinson's disease (PD) is common, and it appears to worsen the motor and cognitive progression of the disease, and limits the patient's quality of life. In this paper, we review the pharmacotherapy of depression in people with PD. We find that evidence is sparse when it comes to this patient population. There is some evidence that older tricyclic antidepressants (nortriptyline and desipramine) may be effective in this population. There is also growing evidence that newer antidepressants like paroxetine and venlafaxine may be effective. We will also review a number of other promising medication treatments. What is apparent is the need for more research identifying the most effective medications for treating depression in this population. We provide recommendations that fall in line with current evidence-based practice for managing depression in the general population. Also, we suggest that collaborative models of depression care may be a promising approach to support the identification and effective treatment of those with PD also suffering from depressive disorders.
 Clinical Neurology Life Sciences & Biomedicine Neurosciences & Neurology Science & Technology

Details

Metrics

8 Record Views
12 Times Cited - Web of Science
Logo image